• Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J.S., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, D.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. & Hillmen, P., On behalf of the UK National Cancer Research Institute (NCRI) Haematological Oncology Clinial Studies Group and NCRI Chronic Lymphocytic Laukaemia Working Group (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 370, 230239.
  • Chena, C., Avalos, J.S., Bezares, R.F., Arrossagaray, K., Turdo, K., Bistmans, A. & Slavutsky, I. (2008) Biallelic deletion 13q14.3 in patients with chronic lymphocytic leukemia: cytogenetic, FISH and clinical studies. European Journal of Haematology, 81, 9499.
  • Cimmino, A., Calin, G.A., Fabbri, M., Iorio, M.V., Ferracin, M., Shimizu, M., Wojic, S.E., Aqeilan, R.I., Zupo, S., Dono, M., Rassenti, L., Alder, H., Volinia, S., Liu, C., Kipps, T.J. & Croce, C.M. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 102, 1394413949.
  • Contal, C. & O’Quigley, J. (1999) An application of changepoint methods in studying the effect of age on survival in breast cancer. Computational Statistics and Data Analysis, 30, 253270.
  • Dewald, G.W., Brockman, S.R., Paternoster, S.F., Bone, N.D., O’Fallon, J.R., Allmer, C., James, C.D., Jelinek, D.F., Tschumper, R.C., Hanson, C.A., Pruthi, R.K., Witzig, T.E., Call, T.G. & Kay, N.E. (2003) Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 121, 287295.
  • Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343, 19101916.
  • Fink, S., Geyer, S., Shanafelt, T., Smoley, S., Paternoster, S., Giordano, K., Tschumper, R., Jelinek, D., Bone, N., Kabat, B., Call, T., Phyliky, R., Kay, N. & Dewald, G. (2004) Clinical significance of homozygous D13S319 deletion in b-cell chronic lymphocytic leukemia (B-CLL). Blood, 104A, 2799.
  • Hernandez, J.A., Rodriguez, A.E., Gonzalez, M., Benito, R., Fontanillo, C., Sandoval, V., Romero, M., Martin-Nunez, G., Garcis de Coca., A., Fisac, R., Galende, J., Recio, I., Ortuno, F., Garcia, J.D., De Las Rivas, J., Gutierrez, N.C., San Miguel, J.F. & Hernandez, J.M. (2009) A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica, 94, 364371.
  • Shanafelt, T.D., Witzig, T.E., Fink, S.R., Jenkins, R.B., Paternoster, S.F., Smoley, S.A., Stockero, K.J., Nast, D.M., Flynn, H.C., Tschumper, R.C., Geyer, S., Zent, C.S., Call, T.G., Jelinek, D.F., Kay, N.E. & Dewald, G.W. (2006) Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 46344641.
  • Tam, C.S., Shanafelt, T.D., Wierda, W.G., Abruzzo, L.V., Van Dyke, D.L., O’Brien, S., Ferajoli, A., Lerner, S.A., Lynn, A., Kay, N.E. & Keating, M.J. (2009) De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the MD Anderson and Mayo Clinic experience. Blood, 114, 957964.